Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | KMO | O15229 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.36 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL112432 | 0.83 | TSHR (0.65) | TSHRMAPTSRD5A2ALDH1A1KMO | |
| SCHEMBL30375607 | 0.83 | TSHR (0.65) | TSHRMAPTSRD5A2ALDH1A1KMO | |
| SCHEMBL320780 | 0.83 | MAPT (0.55) | TSHRMAPTSRD5A2ALDH1A1KMO | |
| SCHEMBL7683262 | 0.82 | MAPT (0.40) | TSHRMAPTALDH1A1MEN1NPC1 | |
| SCHEMBL393467 | 0.81 | PARP1 (0.48) | TSHRMAPTMAOBKDR | |
| SCHEMBL1841487 | 0.81 | MAPT (0.51) | TSHRMAPTMAOBALDH1A1MEN1 | |
| SCHEMBL10882023 | 0.80 | ALDH1A1 (0.38) | TSHRMAPTSRD5A2ALDH1A1NPC1 | |
| SCHEMBL29514652 | 0.79 | TSHR (0.67) | TSHRMAPTSRD5A2KMOKDM4E | |
| SCHEMBL110094 | 0.79 | TSHR (0.67) | TSHRMAPTSRD5A2KMOKDM4E | |
| SCHEMBL2268166 | 0.78 | ALDH1A1 (0.37) | TSHRMAPTALDH1A1KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260097139-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GnRHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY INC (US) | 2026-04-09 | — | — | US | disclosed |
| EP-4634174-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GNRHR) TARGETED THERAPEUTICS AND USES THEREOF | Radionetics Oncology, Inc. (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250282792-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES, INC. | 2025-09-11 | — | — | US | disclosed |
| US-12281060-B2 | Remodilins for airway remodeling and organ fibrosis | THE UNIVERSITY OF CHICAGO (US) | 2025-04-22 | — | — | US | disclosed |
| US-20240415851-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | THE UNIVERSITY OF CHICAGO (US) | 2024-12-19 | — | — | US | disclosed |
| CN-118439937-A | Synthetic method of 4-fluoro-3-phenoxybenzaldehyde serving as key intermediate of insect repellent | 康龙化成(绍兴)药业有限公司 | 2024-08-06 | — | — | CN | disclosed |
| WO-2024129600-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GNRHR) TARGETED THERAPEUTICS AND USES THEREOF | RADIONETICS ONCOLOGY, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| US-11713324-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220177422-A1 | REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS | THE UNIVERSITY OF CHICAGO (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220040207-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | THE UNIVERSITY OF CHICAGO (US) | 2022-02-10 | — | — | US | disclosed |
| EP-0126225-B1 | PROCESS FOR THE PREPARATION OF SUBSTITUTED TRIALKYLSILYLOXYMALONIC-ACID DINITRILES | BAYER AG (DE) | 1986-11-26 | — | — | EP | disclosed |
| US-4620022-A | REACTING TRIALKYLSILYL CYANIDE WITH ACID HALIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1986-10-28 | — | — | US | disclosed |
| US-4555370-A | CYANTATION OF ACYL. FLUORIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1985-11-26 | — | — | US | disclosed |
| EP-0126225-A1 | Process for the preparation of substituted trialkylsilyloxymalonic-acid dinitriles | BAYER AG (DE) | 1984-11-28 | — | — | EP | disclosed |
| EP-0038987-B1 | PROCESS FOR PREPARING ACYL CYANIDES | BAYER AG (DE) | 1983-06-08 | — | — | EP | disclosed |
| EP-0024516-B1 | 4-FLUORO-3-BROMOBENZOYL FLUORIDE, PROCESS FOR ITS PREPARATION AND FOR THE PREPARATION OF 4-FLUORO-3-BROMOBENZOIC ACID THEREFROM | BAYER AG (DE) | 1982-07-28 | — | — | EP | disclosed |
| EP-0038987-A1 | Process for preparing acyl cyanides | BAYER AG (DE) | 1981-11-04 | — | — | EP | disclosed |
| EP-0024516-A1 | 4-Fluoro-3-bromobenzoyl fluoride, process for its preparation and for the preparation of 4-fluoro-3-bromobenzoic acid therefrom | BAYER AG (DE) | 1981-03-11 | — | — | EP | disclosed |
| US-4187230-A | Preparation of 5-aroyl-pyrrole compounds | ETHYL CORPORATION (US) | 1980-02-05 | — | — | US | disclosed |
| US-3952012-A | MULTISTAGE | MCNEIL LABORATORIES, INCORPORATED (US) | 1976-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220040207-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | HIF1AN, RHOXF2, HIF1A | TSHR 3276/4885MAPT 4394/4885MAOB 4667/4885 |
| US-20260097139-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR (GnRHR) TARGETED THERAPEUTICS AND USES THEREOF | GNRHR, GHRHR, FSHR | TSHR 28/4885MAPT 4193/4885MAOB 2607/4885 |
| US-20220177422-A1 | REMODILINS FOR AIRWAY REMODELING AND ORGAN FIBROSIS | MYLK, MFAP1, FIBP | TSHR 3401/4885MAPT 4699/4885MAOB 4661/4885 |
| US-20250282792-A1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | GNRHR, GHRHR, LHCGR | TSHR 56/4885MAPT 4248/4885MAOB 954/4885 |
| US-11713324-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | TSHR 56/4885MAPT 4248/4885MAOB 954/4885 |
| US-12281060-B2 | Remodilins for airway remodeling and organ fibrosis | MYLK, MFAP1, FIBP | TSHR 3401/4885MAPT 4699/4885MAOB 4661/4885 |
| US-20240415851-A1 | REMODILINS TO PREVENT OR TREAT CANCER METASTASIS, GLAUCOMA, AND HYPOXIA | HIF1AN, RHOXF2, HIF1A | TSHR 3276/4885MAPT 4394/4885MAOB 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.